/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Andrew was born in Melbourne, Australia and studied Medicine at Oxford and Cambridge. He has published over 20 patents and 750 papers with 160,000 career citations, and an H-index of 160.
He served as Editor-in-Chief of the International Journal of Cardiology from 1999 to 2016. Andrew is an expert on heart failure. He first described the Muscle Hypothesis of Chronic Heart Failure that explained dyspnoea and exaggerated ventilatory responses in CHF patients. He first described chemoreflex overactivity as cause of periodic breathing in CHF and published the first ever randomised trial of exercise training for CHF. Andrew has been Chairman or Committee member of the following major Cardiovascular and Cancer Cachexia Clinical Trials: CHRISTMAS, CHARM, COPERNICUS, OXAM, OPTIMAAL, OVERTURE, REPLACE, SENIORS, AUGMENTHF and ACT-ONE. He was Head of Cardiology at Imperial College, London and Dean of Medicine at the University of Sydney. He was President of the Heart Failure Association 2020-22.
- …
